Protective Immunogenicity of Group A Streptococcal M-Related Proteins

被引:15
|
作者
Dale, James B. [1 ,2 ,3 ]
Niedermeyer, Shannon E. [1 ,3 ]
Agbaosi, Tina [1 ,3 ]
Hysmith, Nicholas D. [1 ,3 ,4 ]
Penfound, Thomas A. [1 ,3 ]
Hohn, Claudia M. [1 ,3 ]
Pullen, Matthew [1 ,3 ]
Bright, Michael I. [1 ,3 ]
Murrell, Daniel S. [1 ,3 ]
Shenep, Lori E. [1 ,3 ]
Courtney, Harry S. [1 ,3 ]
机构
[1] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN 38104 USA
[2] Univ Tennessee, Dept Microbiol Immunol & Biochem, Hlth Sci Ctr, Memphis, TN 38104 USA
[3] Dept Vet Affairs Med Ctr, Memphis, TN USA
[4] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
关键词
RHEUMATIC HEART-DISEASE; VACCINE; PYOGENES; PREVALENCE; GENE; IDENTIFICATION; EPITOPES; CHILDREN; BINDING; ECHOCARDIOGRAPHY;
D O I
10.1128/CVI.00795-14
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Many previous studies have focused on the surfaceMproteins of group A streptococci (GAS) as virulence determinants and protective antigens. However, the majority of GAS isolates express M-related protein (Mrp) in addition toMprotein, and both have been shown to be required for optimal virulence. In the current study, we evaluated the protective immunogenicity of Mrp to determine its potential as a vaccine component that may broaden the coverage ofMprotein-based vaccines. Sequence analyses of 33 mrp genes indicated that there are three families of structurally related Mrps (MrpI, MrpII, and MrpIII). N-terminal peptides of Mrps were cloned, expressed, and purified fromMtype 2 (M2) (MrpI), M4 (MrpII), and M49 (MrpIII) GAS. Rabbit antisera against the Mrps reacted at high titers with the homologous Mrp, as determined by enzyme-linked immunosorbent assay, and promoted bactericidal activity against GAS emm types expressing Mrps within the same family. Mice passively immunized with rabbit antisera against MrpII were protected against challenge infections with M28 GAS. Assays for Mrp antibodies in serum samples from 281 pediatric subjects aged 2 to 16 indicated that the Mrp immune response correlated with increasing age of the subjects. Affinity-purified human Mrp antibodies promoted bactericidal activity against a number of GAS representing different emm types that expressed an Mrp within the same family but showed no activity against emm types expressing an Mrp from a different family. Our results indicate that Mrps have semiconserved N-terminal sequences that contain bactericidal epitopes which are immunogenic in humans. These findings may have direct implications for the development of GAS vaccines.
引用
收藏
页码:344 / 350
页数:7
相关论文
共 50 条
  • [11] Immunogenicity and protective efficacy of Clostridium difficile spore proteins
    Ghose, Chandrabali
    Eugenis, Ioannis
    Edwards, Adrianne N.
    Sun, Xingmin
    McBride, Shonna M.
    Ho, David D.
    ANAEROBE, 2016, 37 : 85 - 95
  • [12] Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections
    Shet, A
    Kaplan, E
    Johnson, D
    Cleary, PP
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2004, 119 : 95 - 98
  • [13] Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults
    Kotloff, KL
    Fattom, A
    Basham, L
    Hawwari, A
    Harkonen, S
    Edelman, R
    VACCINE, 1996, 14 (05) : 446 - 450
  • [14] Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197
    Caro-Aguilar, Ivette
    Ottinger, Elizabeth
    Hepler, Robert W.
    Nahas, Deborah D.
    Wu, Chengwei
    Good, Michael F.
    Batzloff, Michael
    Joyce, Joseph G.
    Heinrichs, Jon H.
    Skinner, Julie M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (03) : 488 - 496
  • [15] Potential coverage of a multivalent M protein-based group A streptococcal vaccine
    Dale, James B.
    Penfound, Thomas A.
    Tamboura, Boubou
    Sow, Samba O.
    Nataro, James P.
    Tapia, Milagritos
    Kotloff, Karen L.
    VACCINE, 2013, 31 (12) : 1576 - 1581
  • [16] Recombinant, octavalent group A streptococcal M protein vaccine
    Dale, JB
    Simmons, M
    Chiang, EC
    Chiang, EY
    VACCINE, 1996, 14 (10) : 944 - 948
  • [17] Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins
    Xiang, Zhi-hao
    Sun, Rui-feng
    Lin, Chen
    Chen, Fu-zeng
    Mai, Jun-tao
    Liu, Yu-xiao
    Xu, Zi-yan
    Zhang, Lu
    Liu, Jun
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [18] Colour Doppler echocardiography in children with group A streptococcal infection related tic disorders
    Cardona, F
    Romano, A
    Cundari, G
    Ventriglia, F
    Versacci, P
    Orefici, G
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2004, 119 : 186 - 190
  • [19] Conserved anchorless surface proteins as group A streptococcal vaccine candidates
    Anna Henningham
    Emiliano Chiarot
    Christine M. Gillen
    Jason N. Cole
    Manfred Rohde
    Marcus Fulde
    Vidiya Ramachandran
    Amanda J. Cork
    Jon Hartas
    Graham Magor
    Steven P. Djordjevic
    Stuart J. Cordwell
    Bostjan Kobe
    Kabada S. Sriprakash
    Victor Nizet
    G. S. Chhatwal
    Immaculada Y. R. Margarit
    Michael R. Batzloff
    Mark J. Walker
    Journal of Molecular Medicine, 2012, 90 : 1197 - 1207
  • [20] In vivo screen of genetically conserved Streptococcus pneumoniae proteins for protective immunogenicity
    Anderson, Richard J.
    Guru, Siradanahalli
    Weeratna, Risini
    Makinen, Shawn
    Falconer, Derek J.
    Sheppard, Neil C.
    Lang, Susanne
    Chang, Bingsheng
    Goenaga, Anne-Laure
    Green, Bruce A.
    Merson, James R.
    Gracheck, Stephen J.
    Eyles, Jim E.
    VACCINE, 2016, 34 (50) : 6292 - 6300